EUVIMEDDécouvrir EUVIMED
Open access

Early initiation of glecaprevir/pibrentasvir after transplantation of HCV‐viremic kidneys into HCV‐negative recipients is associated with normalization in the altered inflammatory milieu

Myung-Ho Kim iD, Meghan E Sise, Min Xu, David S Goldberg, Robert J Fontana, Jens J Kort, Rita R Alloway, Christine M Durand, Robert S Brown, Josh Levitsky, Jenna L Gustafson, Peter P Reese and 1 more

Clinical Transplantation · 2023

DOI: 10.1111/ctr.14926 ↗

At a glance

Journal article in Clinical Transplantation, 2023. Written by Myung-Ho Kim and 12 co-authors. Institution: Liver Center, Gastrointestinal Division, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA. Major MEDLINE topics: Hepatitis C, Chronic, Hepatitis C. Cited 1 times so far (Crossref); 23 references. The full text is freely available in PubMed Central. Funded by: NIDDK NIH HHS.

RésuméSubjectsRéférences bibliographiquesCiteRelated studies

Abstract (original language)

Our previous Multicenter Trial to Transplant HCV‐infected Kidneys (MYTHIC) observed that 100% of hepatitis C virus (HCV)‐uninfected patients who received a kidney from an HCV‐infected deceased donor were cured of HCV with an 8‐week regimen of glecaprevir and pibrentasvir (G/P) initiated 2–5 days after transplantation. Following acute and chronic infection with HCV, immune system perturbations have been reported to persist even after viral clearance. The aim of this study was to determine whether HCV viremic kidney recipients in the MYTHIC study experience sustained changes in the soluble inflammatory milieu associated with HCV infection. Among nine patients with HCV viremia at day 3 post‐kidney transplant (post‐KT D3), IP‐10, IL‐10, MIP‐1β, and IL‐8 were significantly elevated from baseline. However, over the subsequent visits, there was a rapid, dramatic reduction back to baseline levels. Among seven patients who were not HCV viremic at post‐KT D3, the cytokine levels did not significantly change. HCV‐uninfected patients who received a kidney from an HCV‐viremic deceased donor and were treated with early G/P experienced only transient alterations in the soluble inflammatory milieu. These data provide reassuring evidence that there appear to be no persistent cytokine disturbances with transient HCV viremia accompanying HCV donor positive/recipient negative kidney transplant.

Subjects

MeSH terms (MEDLINE)

Hepatitis C, ChronicHepatitis CHumansHepacivirusViremiaAntiviral AgentsKidneyTissue DonorsCytokinesAminoisobutyric AcidsCyclopropanesLeucineProlineQuinoxalinesSulfonamidesLactams, MacrocyclicBenzimidazolesPyrrolidinesDrug Combinations

Author keywords

biomarkerimmune regulationinfection and infectious agentsviral: hepatitis C

Substances

Antiviral AgentsCytokinesglecaprevirAminoisobutyric AcidsCyclopropanesLeucineProlineQuinoxalinesSulfonamidesLactams, Macrocyclic

Authors and institutions

  • Liver Center, Gastrointestinal Division, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Nephrology Division, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Division of Digestive Health & Liver Diseases, University of Miami Miller School of Medicine, Miami, Florida, USA.
  • Division of Gastroenterology & Hepatology, University of Michigan Medical School, Ann Arbor, Michigan, USA.
  • Global Medical Affairs Research & Development, AbbVie Inc., North Chicago, Illinois, USA.
  • Division of Nephrology, Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.

ORCID profiles: Myung-Ho Kim

Funding

  • NIDDK NIH HHS

Cite

APA

Kim, M. H., Sise, M. E., Xu, M., Goldberg, D. S., Fontana, R. J., Kort, J. J., Alloway, R. R., Durand, C. M., Brown, R. S., Levitsky, J., Gustafson, J. L., Reese, P. P., & Chung, R. T. (2023). Early initiation of glecaprevir/pibrentasvir after transplantation of HCV‐viremic kidneys into HCV‐negative recipients is associated with normalization in the altered inflammatory milieu. Clinical Transplantation. https://doi.org/10.1111/ctr.14926

Vancouver

Kim MH, Sise ME, Xu M, Goldberg DS, Fontana RJ, Kort JJ, et al. Early initiation of glecaprevir/pibrentasvir after transplantation of HCV‐viremic kidneys into HCV‐negative recipients is associated with normalization in the altered inflammatory milieu. Clinical Transplantation. 2023. doi:10.1111/ctr.14926

BibTeX
@article{Kim2023,
  author = {Kim, Myung-Ho and Sise, Meghan E and Xu, Min and Goldberg, David S and Fontana, Robert J and Kort, Jens J and Alloway, Rita R and Durand, Christine M and Brown, Robert S and Levitsky, Josh and Gustafson, Jenna L and Reese, Peter P and Chung, Raymond T},
  title = {Early initiation of glecaprevir/pibrentasvir after transplantation of HCV‐viremic kidneys into HCV‐negative recipients is associated with normalization in the altered inflammatory milieu},
  journal = {Clinical Transplantation},
  year = {2023},
  doi = {10.1111/ctr.14926}
}
Start for free →